蛋白磷酸酶2A的癌性抑制因子在小细胞肺癌组织中的表达及临床意义

Expression and clinical significance of CIP2A in small cell lung cancer patients

目的探讨小细胞肺癌组织中蛋白磷酸酶2A的癌性抑制因子（CIP2A）的表达及其与临床病理特征及预后的关系。方法选取2008年1月至2013年2月行手术切除或支气管镜活检、临床资料完整的94例小细胞肺癌组织及40例癌旁组织（距病灶≥2cm的组织）标本，分析CIP2A在小细胞肺癌组织中的表达及其与临床病理特征和预后的关系。结果CIP2A mRNA在94例小细胞肺癌组织中的表达水平为7．605±1．893，与40例癌旁组织（1．041±0．786）比较，差异有统计学意义（P〈0．001）。CIP2A蛋白在小细胞肺癌组织中的阳性表达率为82．8％，与癌旁组织（13．3％）比较，差异有统计学意义（P〈0．01）。CIP2A高表达患者的中位无病生存时间为9.88个月，低于低表达患者（20．92个月），差异有统计学意义（P〈0．001）。CIP2A的表达与肿瘤分期、化疗药物敏感性和生存时间均有关（均P〈0．05）。结论CIP2A的表达情况与小细胞肺癌的发生发展有关，CIP2A检测有望作为小细胞肺癌的预后指标。

Objective To explore the expression of cancerous inhibitor of phosphatase 2A （CIP2A） protein in small cell lung cancer and their relationship with clinicpathological features and prognosis. Methods A total of 112 cases of surgical specimens or bronchoscopic biopsies of small cell lung cancer were collected. There were specimens of 94 cases of SCLC tissues and 40 cases of paracancerous lung tissues. Quantitative RT-PCR and immunohistochemistry analysis were performed to determine the CIP2A expression in SCLC tissues. Kaplan-Meier curves were used to estimate the association between CIP2A expression and clinicopathological characteristics and prognosis of the patients. Results The expression of CIP2A in SCLC tissue was 7.605±1.893, significantly higher than that in the paracancerous tissues （ 1. 041 ± 0.786） （ P〈 0.01 ）. The positive rate of CIP2A expression in cancer tissues was 82.8%, significantly higher than that in the paracancerous tissues （13.3%） （P〈0.01）. The median disease-free survival was 9.88 months in the CIP2A-high expressing patients, significantly shorter than the 20. 92 months in CIP2A-low expressing patients （P〈0.001）. CIP2A expression was significantly correlated with the tumor stage, chemotherapeutic sensitivity, and survival （P 〈 0. 05 for all ）. Conclusions CIP2A expression is associated with the pathogenesis of SCLC, and may become a potential prognostic indicator of SCLC.